BillionToOne
A Rare Opportunity to Shape the Future of Genomics Join a team of brilliant, passionate innovators determined to transform healthcare. At BillionToOne, we've built a category-defining, publicly traded company on Nasdaq where transparency fuels trust, collaboration drives breakthroughs, and every contribution moves the needle on our mission to make life-changing diagnostics accessible to all. We don't just aim for incremental improvements; we build products that are 10x better than anything that exists today. Our scientists, engineers, sales executives, and visionaries are united by an unwavering commitment to changing the standard of care in prenatal and cancer diagnostics. This is where cutting-edge science meets human compassion, and every innovation you contribute helps remove the fear of the unknown from some of life's most critical medical moments. If you're driven by purpose, energized by innovation, and ready to help shape the future of precision medicine at scale, this is where you belong. We are seeking an entrepreneurial and highly strategic leader for the Head of Strategic Pharma Partnerships, Oncology role. This position is pivotal in driving BillionToOne’s growth by forging impactful partnerships with pharmaceutical companies and exploring innovative product opportunities in the precision diagnostics and oncology space. The role combines business development expertise with product exploration to identify and validate new use cases for our oncology liquid biopsy solutions. The ideal candidate will have a strong understanding of both the technical and commercial aspects of precision diagnostics, excel in customer engagement, and thrive in a fast-paced, dynamic environment. This role reports to the Chief Product Officer.
Actively identify and engage pharmaceutical companies to build strategic partnerships for BillionToOne’s oncology product lines. Negotiate and close partnership agreements that drive business growth and align with our strategic goals. Represent BillionToOne at industry conferences and events to establish and strengthen relationships with key stakeholders. Collaborate with internal teams (R&D, Clinical, and AI) to identify new product opportunities and validate their potential with pharmaceutical partners. Act as the primary advocate for pharmaceutical customers, deeply understanding their needs and translating them into actionable product insights. Partner with internal teams to co-develop solutions that address unmet needs in oncology diagnostics. Work with Clinical and R&D teams to align on technical feasibility and ensure smooth execution of partnership projects. Collaborate with legal and finance teams to structure and finalize deal terms. Maintain a feedback loop with internal stakeholders to iterate on product concepts and improve partnership success rates.
10+ years of experience in business development, product partnerships, or a related role in precision diagnostics or life sciences. Proven track record of closing complex deals with pharmaceutical companies. Strong understanding of oncology diagnostics and liquid biopsy technologies. Ability to bridge the gap between technical teams and business stakeholders, translating scientific concepts into commercial opportunities. Exceptional communication and relationship-building skills. Entrepreneurial mindset with a passion for product innovation and customer success. Strategic thinker with the ability to execute effectively in a dynamic, fast-paced environment. Willingness to travel (up to 25%) to engage partners and attend key industry events.
Working alongside brilliant, kind, passionate and dedicated colleagues, in an empowering environment, toward a global vision, striving for a future in which transformative molecular diagnostics can help millions of patients Open, transparent culture that includes weekly Town Hall meetings The ability to indirectly or directly change the lives of hundreds of thousand patients Multiple medical benefit options; employee premiums paid 100% of select plans, dependents covered up to 80% Extremely generous Family Bonding Leave for eligible employees (16 weeks, paid at 100%) Supplemental fertility benefits coverage Retirement savings program including a 4% Company match Increase paid time off with increased tenure Latest and greatest hardware (laptop, lab equipment, facilities) At BillionToOne, we are proud to offer a combination of a (1) base pay range (actual amount offered is based on experience and salary/equity options split that the candidate chooses), (2) generous equity options offering, (3) corporate bonus program, on top of (4) industry leading company benefits (free healthcare options, 401k match, very generous fully paid parental leave, etc.). For this position, we offer a total compensation package of $397,170 to $400,402 per year, including a base pay range of $242,881 to $264,002 per year. BillionToOne is an equal opportunity employer. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status. For more information about how we protect your information, we encourage you to review our Privacy Policy . BillionToOne is a next-generation molecular diagnostics company on a mission to make powerful, accurate diagnostic tests accessible to everyone. Our revolutionary QCT molecular counting technology enhances disease detection resolution by over a thousandfold using cell-free DNA,a breakthrough that has already transformed the lives of over half a million patients worldwide. Our Impact Unity Complete™ is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Unity Confirm™ enables non-invasive confirmation for high-risk screening results through the capture of intact circulating fetal cells using BillionToOne’s Fetal Cell Capture™ Technology. Our Northstar® liquid biopsy test uniquely combines treatment selection with real-time monitoring, giving oncologists unprecedented precision in cancer care. Our Growth From $0 to $400M+ annualized revenue run-rate in just 6 years. In 2025, we completed one of the most successful IPOs for a medical diagnostics company, building on nearly $400M in private funding,including our $130M Series D in 2024 and backed by world-class investors including Hummingbird, Adams Street Partners, Neuberger Berman, Baillie Gifford, and Premji Invest. Our Recognition Forbes named us one of America's Best Startup Employers for 2025 and we're Great Place to Work certified , with 100% of our people willing to go the extra mile, even as we've scaled to over 700 employees. Our Future Headquartered in Menlo Park with facilities in Union City, CA, and a new lab opening in Austin, TX in 2027, we're continuing to push the boundaries of what's possible in molecular diagnostics. We're just getting started. Ready to help us change the world, one molecule at a time? Learn more at billiontoone.com